Pulmatrix doses first patient in Ph1 Pulmazole trial

Pulmatrix (NSDQ:PULM) said today that the first patient was treated in a first-in-human study of Pulmazole – an inhaled formulation of the anti-fungal drug, itraconazole. The Lexington, Mass.-based company is evaluating its iSperse formulation of the drug as a treatment for asthma patients who have developed allergic bronchopulmonary aspergillosis. Get the full story at our sister site, Drug Delivery Business News. The post Pulmatrix doses first patient in Ph1 Pulmazole trial appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Pulmatrix Inc. Source Type: news

Related Links:

Aspergillus fumigatus is a ubiquitous ascomycete mould that can cause a wide spectrum of clinical syndromes. The pathological effects of A. fumigatus depend largely on the interplay between the pathogen and host immune response ranging from asymptomatic colonisation to life-threatening infection. Invasive aspergillosis (IA), the most severe form of A. fumigatus infection, predominantly affects immunocompromised patients. In contrast, immune hyperactivity can lead to allergic bronchopulmonary aspergillosis (ABPA) and fungal sensitization in severe asthma (SAFS).
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Source Type: research
CONCLUSIONS: This study showed that serum miR-1165-3p can potentially be utilized as a noninvasive biomarker that is able to aid in the diagnosis and characterization of allergic asthma. PMID: 30015513 [PubMed - as supplied by publisher]
Source: Biomarkers - Category: Research Tags: Biomarkers Source Type: research
Wednesday, July 18, 2018 - 13:05Slide presentation
Source: The Aspergillus Website - updates - Category: Respiratory Medicine Authors: Source Type: news
Pulmatrix (NSDQ:PULM) said today that all dosing and follow-up visits have finished for its first-in-human study of an inhaled formulation of itraconazole as a treatment of allergic bronchopulmonary aspergillosis in people with asthma. The inhaled iSperse formulation, called Pulmazole, was well-tolerated, according to the Lexington, Mass.-based company. Pulmatrix plans to launch a Phase II trial of its ABPA therapy in the fourth quarter this year. Get the full story at our sister site, Drug Delivery Business News. The post Pulmatrix touts data from first-in-human trial of inhaled anti-fungal therapy appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Wall Street Beat Pulmatrix Inc. Source Type: news
Abstract There has been an increase in fungal infections in patients with chronic lung disease over the past decades, which is associated with rapidly increasing costs to healthcare systems.An antifungal stewardship team was introduced to a tertiary cardiopulmonary hospital, consisting of a medical mycologist and pharmacy support providing weekly stewardship ward rounds, twice monthly multidisciplinary team meetings and a dedicated weekly outpatient clinic. A database was set up to record the activity of the stewardship team.During the first eighteen months of implementation the antifungal stewardship team had revie...
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Tags: Antimicrob Agents Chemother Source Type: research
Valliappan Muthu, Inderpaul Singh Sehgal, Sahajal Dhooria, Amanjit Bal, Ritesh AgarwalLung India 2018 35(4):332-335 Allergic bronchopulmonary aspergillosis (ABPA) is a complex inflammatory lung disorder complicating bronchial asthma and cystic fibrosis. Although the condition responds to treatment with glucocorticoids and antifungal drugs, lack of timely recognition, and inadequate treatment of ABPA can lead to progressive lung damage. Uncommonly, long standing inflammation and bronchiectasis can also lead to the development of secondary amyloidosis. Herein, we report a case of ABPA, which presented as nephrotic syndrome ...
Source: Lung India - Category: Respiratory Medicine Authors: Source Type: research
Source: Journal of Asthma and Allergy - Category: Allergy & Immunology Tags: Journal of Asthma and Allergy Source Type: research
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Poster Sessions Source Type: research
The finding of pulmonary eosinophilia elicits a broad differential diagnosis (Table 1).1 –3 Attention to key differentiating histologic features combined with clinical and laboratory findings and pertinent radiologic findings are important for distinguishing among the most common entities in the differential diagnosis that include eosinophilic pneumonia, eosinophilic granulomatosis wi th polyangiitis (EGPA, formerly Churg-Strauss syndrome), allergic bronchopulmonary aspergillosis (ABPA) or more generally allergic bronchopulmonary fungal disease (ABPFD) and isolated asthma.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Review Articles Source Type: research
This study, we described 10 patients (6 male and 4 female) with SCID who were admitted to Mofid Children Hospital, Tehran, Iran, from 2006 to 2013. We reviewed patients' clinical manifestation, laboratory data, family history and outcome. The mean age at the time of diagnosis was 131.8 days. One patient had non-consanguineous parents. Seven patients received BCG vaccine before the diagnosis of SCID, three of them showed disseminated BCG infection. One patient presented with invasive pulmonary aspergillosis. Flow cytometric analysis showed T⁻B⁺NK⁻ in three patients, T⁻B⁻NK⁺ in five patients, T⁻B⁻NK⁻ in one...
Source: Iranian Journal of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Iran J Allergy Asthma Immunol Source Type: research
More News: Allergy & Immunology | Aspergillosis | Asthma | Clinical Trials | Respiratory Medicine | Study